Haleos Labs Ltd

Haleos Labs Business Update

USFDA inspected the material subsidiary Mahi Drugs' API facility in Parawada. The inspection concluded with zero Form 483 observations.

Haleos Labs Other Announcement

Haleos Labs Ltd notified shareholders of the Annual Report and AGM notice weblink, while requesting updates to their KYC and email addresses.

Haleos Labs Annual Report

Haleos Labs Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice for its 20th Annual General Meeting.

Haleos Labs Dividend

Haleos Labs Limited recommended a final dividend of ₹15 per equity share for FY 2025-26. The record date is fixed for September 23, 2026.

Haleos Labs Annual General Meeting

Haleos Labs Limited announced postal ballot results where shareholders approved director reappointment and related party transactions. However, a resolution for managerial remuneration was rejected by shareholders.

Haleos Labs Management Change

Haleos Labs Limited has re-appointed Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for five-year terms starting November 13, 2026. Shareholder approval is required.

Execution

5 years

Haleos Labs Q1 FY27 Results: Net Profit ₹1.8 Cr, Down 59.1% YoY

Haleos Labs Ltd reported revenue from operations of ₹72.9 Cr (-11.6% YoY) and net profit of ₹1.8 Cr (-59.1% YoY) for Q1 FY27.

Key figure

Net profit ₹1.8 Cr · -59.1% YoY

Haleos Labs Board Meeting Date

Haleos Labs Ltd has scheduled a board meeting for August 5, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.

Haleos Labs Annual General Meeting

Haleos Labs Limited issued a postal ballot notice seeking shareholder approval for director reappointment, managerial remuneration limits, and material related party transactions.

Value

₹190.7 Cr

Haleos Labs Annual General Meeting

Haleos Labs Limited issued a postal ballot notice for shareholder approval regarding director reappointment, managerial remuneration, and various material related party transactions.

Value

₹200.6 Cr

Haleos Labs Annual General Meeting

Haleos Labs has announced a postal ballot process to seek shareholder approval for various resolutions, including director reappointment, managerial remuneration, and related party transactions.

Haleos Labs Other Announcement

Haleos Labs is transferring shares to the IEPF suspense account for unclaimed dividends from FY 2018-19. This is a routine regulatory compliance with no material financial impact.

Haleos Labs Other Announcement

Haleos Labs Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no new fines.

Haleos Labs Management Change

Haleos Labs Limited re-appointed Sudeepthi Gopineedi as Executive Director while Independent Director Sundaramma Patibandla resigned. The board also appointed new statutory and cost auditors.

Haleos Labs Management Change

Haleos Labs appointed Suryanarayana & Suresh as Statutory Auditors for five years. Annapragada & Co. was also reappointed as Cost Auditors for fiscal 2026-27.

Execution

5 years

Haleos Labs Management Change

Mrs. Sundaramma Patibandla resigned as Independent Director of Haleos Labs Limited effective May 29, 2026. The board remains compliant with SEBI governance requirements post-resignation.

Haleos Labs Dividend

Haleos Labs Limited recommended a final dividend of ₹15 per equity share for FY 2026-27. The payout remains subject to shareholder approval at the general meeting.

Value

₹15.00 Cr

Haleos Labs Q4 FY26 Results: Net Profit ₹0.3 Cr, Down 91.4% YoY

Haleos Labs Ltd reported revenue from operations of ₹75.1 Cr (-15.7% YoY) and net profit of ₹0.3 Cr (-91.4% YoY) for Q4 FY26.

Key figure

Net profit ₹0.3 Cr · -91.4% YoY

Haleos Labs Financial Results

Haleos Labs reported audited FY26 financial results and recommended a ₹1.50 per share dividend. The board also approved senior management reappointments and auditor changes.

Haleos Labs Board Meeting Date

Haleos Labs Limited scheduled a board meeting for May 29, 2026, to approve audited annual financial results. Directors will also discuss recommending a dividend.

Haleos Labs Credit Rating

Infomerics reaffirmed credit ratings for Haleos Labs and its subsidiary for ₹136.76 Crore in facilities. The outlook remains positive, reflecting stable operational performance.

Value

₹136.8 Cr

Execution

Valid until May 20, 2027

Haleos Labs Annual General Meeting

Haleos Labs Limited shareholders approved a material related party transaction involving a corporate guarantee for RBL Bank. The guarantee secures an External Commercial Borrowing facility for its subsidiary, Mahi Drugs Private Limited. The resolution was passed with a 99.99% majority via postal ballot.

Haleos Labs Other Announcement

Haleos Labs Ltd submitted its quarterly RTA compliance certificate for the period ended March 31, 2026. The certificate confirms compliance with SEBI dematerialisation regulations, including the cancellation of physical security certificates. This is a routine regulatory disclosure with no immediate financial impact.

Haleos Labs Promoter Reclassification

Haleos Labs Ltd has received annual declarations from erstwhile promoters Mr. Suresh Babu Potluri and Mr. Hari Kishore Potluri. They confirm continued compliance with SEBI's reclassification norms, holding less than 10% voting rights and exercising no control over the company. This maintains their status within the public shareholding category.